



Benjamin Shobert
Senior Associate, National Bureau of Asian Research

Benjamin Shobert is Senior Associate for International Health at NBR. He advises and contributes to NBR research programs on international health in Asia.

Mr. Shobert is also the Director of Strategy for health business strategy at Microsoft, where he leads strategy engagements with national governments, providers, and the biotech community. Prior to joining Microsoft, he was Founder and Managing Director of Seattle-based Rubicon Strategy Group, a boutique consulting firm that specializes in market access work in China's healthcare, life science, and senior care industries. In 2013, Rubicon completed the first syndicated research report on Myanmar's healthcare system.

For six years, Mr. Shobert wrote a column for the Asia Times on U.S.-China trade and economic policy, with a particular focus on how relations between the two countries were affected after the 2008 financial crisis. His latest book, *Blaming China: It Might Feel Good but It Won't Fix America's Economy*, explores the future of U.S.-China economic and political relations.

Mr. Shobert testified before the Commission in April 2014 on "China's Healthcare Sector, Drug Safety, and the U.S.-China Trade in Medical Product."

Questions for the Panelist

- What health products or services are Chinese firms providing in the United States, and how have these products/services changed over the last 5 years?
- What genomic research have Chinese entities provided to U.S. companies or individuals? What concerns, if any, should policy makers have regarding these activities?
- Do Chinese government regulations managing the production and export of health products and medicines sufficiently address potential public health concerns?
- What are the trends and implications of Chinese investment in the U.S. health, biotech, and pharmaceutical industries?
- How do Chinese investments, cooperative research ventures, intellectual property theft, and other activities in health and pharmaceutical industries advance China's interests, and do they present a threat to U.S. economic or national security interests?
- Is the U.S. government adequately equipped to address risks to U.S. public health or national security posed by China's role in medical, pharmaceutical, and biotech supply chains?
- What recommendations would you propose for Congressional consideration?